Welcome to the First 2021 Issue of The CLL Society Tribune
Spring is in the air and we are still locked down but sense a cautious optimism that the post-pandemic world may soon be near, even for the most vulnerable of us who either have CLL or are caring for someone with this diagnosis.
We are pleased to bring you the first edition of the 2021 CLL Society Tribune, full of articles from patients and experts to inspire, educate, and guide you towards advocating for your best care, wherever you are in your CLL journey.
We are all in this together.
Co-founder & Communications Director
Read Mark’s exciting report how he is still MRD Undetectable (UMRD) in the blood after 3 years in the Captivate clinical trial! Read more
Dr. Fraietta shares how CAR-T cell therapy is well-positioned to become part of routine medical management of CLL. Read more
ASH 2020: Dr. Anthony Mato Discusses the Impact of del(17p) On Survival of Patients with CLL Treated with First-Line Ibrutinib
At the virtual ASH meeting which was held December 2020, Dr. Brian Koffman interviewed Dr. Anthony Mato about new research evaluating the efficacy of ibrutinib as a first-line treatment for patients with CLL and del(17p). Watch The Interview
Questions submitted by readers and answered by our CLL Society experts.
By Richard Furman, MD
Dr. Richard Furman of Weill-Cornell Medical College answers readers’ questions submitted to the CLL Society. Read more
Thomas E Henry III, MBA, RPh, CPh from Burlington Consulting Associates answers readers’ pharmacy questions submitted to the CLL Society. Read more
Susan J. Leclair from University of Massachusetts Dartmouth answers readers’ lab scientist questions submitted to the CLL Society. Read more
The CLL Society Tribune is looking for your contribution including articles, storytelling, poems, drawings, or other creative mediums. Please share!
Email firstname.lastname@example.org with your interest!
The CLL Society Tribune is made possible in part by grant support from AbbVie and Adaptive Biotechnologies.
The CLL Society does not provide medical advice or endorsements. Unless explicitly stated otherwise, all content in the CLL Tribune is the opinion or information of its author, not the CLL Society. This newsletter is for reference and educational purposes only and is not a substitute for medical advice. We do not guarantee the accuracy of any of the materials. Always contact your own doctor or other professional healthcare provider if you have any questions concerning your or your family’s health. Everyone’s circumstances are different.